dsm-firmenich has agreed to sell its share in the Feed Enzymes Alliance to Novonesis, marking a strategic shift in its business portfolio. The company will now focus on separating its Animal Nutrition & Health unit, expected to be completed in 2025.

dsm-firmenich announced the sale of its stake in the Feed Enzymes Alliance to Novonesis for €1.5 billion. The transaction covers a business generating approximately €300 million in annual net sales. dsm-firmenich expects to receive around €1.4 billion in net cash after transaction costs and taxes, with a book profit to be recorded upon closing.

Dimitri de Vreeze

Novonesis, a global biosolutions leader, will maintain a long-term commercial relationship with dsm-firmenich’s Animal Nutrition & Health (ANH) unit, reselling feed enzymes through its global premix network. The sale comes as dsm-firmenich moves forward with its plan to separate the ANH business from the Group. "The Alliance has been a great success for both companies, establishing a global leadership position in feed enzymes," said Dimitri de Vreeze, CEO of dsm-firmenich.

Ester Baiget

Ester Baiget, President and CEO of Novonesis, emphasized the acquisition’s strategic value, noting that rising global protein demand and environmental constraints necessitate innovative solutions. "With an expanded presence across the animal biosolutions value chain, we are better positioned to create more value for customers," she stated.

The deal marks the end of a 25-year partnership between the companies. The transaction is expected to close in 2025, subject to regulatory approvals. Meanwhile, dsm-firmenich will begin seeking buyers for its ANH business next week.